235 related articles for article (PubMed ID: 16280257)
21. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
22. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.
Shimoni A; Nagler A
Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553
[TBL] [Abstract][Full Text] [Related]
23. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
25. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hematopoietic cell transplantation as consolidation immunotherapy of cancer after autologous transplantation.
Maris MB; Storb R
Acta Haematol; 2005; 114(4):221-9. PubMed ID: 16269862
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Kothari A; Ngwube A; Hayashi R; Murray L; Davis J; Haut P; Loechelt BJ; Shenoy S
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1321-5. PubMed ID: 25840334
[TBL] [Abstract][Full Text] [Related]
28. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches.
Friedman TM; Varadi G; Hopely DD; Filicko J; Wagner J; Ferber A; Martinez J; Brunner J; Grosso D; McGuire L; Korngold R; Flomenberg N
Biol Blood Marrow Transplant; 2001; 7(12):656-64. PubMed ID: 11787528
[TBL] [Abstract][Full Text] [Related]
29. [Safety and effectiveness of tumor-ablative chemotherapy combined with low intensity modified conditioning regimen for 30 patients with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation].
Luo RM; Da WM; Hu B; Si YJ; Zhang XM; Du ZL; Liu QH; Wang Y; Yue Y; Chen W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1047-52. PubMed ID: 25130826
[TBL] [Abstract][Full Text] [Related]
30. [Allogeneic hematopoietic stem cell treatment after non-myeloablation (minigraft)].
Baron F
Bull Mem Acad R Med Belg; 2011; 166(1-2):39-45; discussion 46-8. PubMed ID: 22375489
[TBL] [Abstract][Full Text] [Related]
31. [Nonmyeloablative stem cell transplantation as cancer immunotherapy].
Willems E; Baron F; Vanstraelen G; Frère P; Fillet G; Beguin Y
Rev Med Suisse; 2005 Aug; 1(30):1973-7. PubMed ID: 16200942
[TBL] [Abstract][Full Text] [Related]
32. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
Rowley SD; Goldberg SL; Pecora AL; Hsu JS; Brecher BA; Butrin L; Kobbe K; McKiernan P; Preti R
Biol Blood Marrow Transplant; 2004 Nov; 10(11):784-93. PubMed ID: 15505609
[TBL] [Abstract][Full Text] [Related]
33. Differences between the different conditioning regimens for allogeneic stem cell transplantation.
Schattenberg AV; Levenga TH
Curr Opin Oncol; 2006 Nov; 18(6):667-70. PubMed ID: 16988592
[TBL] [Abstract][Full Text] [Related]
34. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
35. Treatment of lymphoid malignancies with non-myeloablative stem cell transplantation.
Seftel MD; Lavoie J; Barnett MJ; Conneally E
Hematology; 2002 Jun; 7(3):151-5. PubMed ID: 12243977
[TBL] [Abstract][Full Text] [Related]
36. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.
Couriel DR; Saliba RM; Giralt S; Khouri I; Andersson B; de Lima M; Hosing C; Anderlini P; Donato M; Cleary K; Gajewski J; Neumann J; Ippoliti C; Rondon G; Cohen A; Champlin R
Biol Blood Marrow Transplant; 2004 Mar; 10(3):178-85. PubMed ID: 14993883
[TBL] [Abstract][Full Text] [Related]
37. Reduced-intensity allogeneic stem cell transplantation.
Bearman SI
Curr Hematol Rep; 2003 Jul; 2(4):277-86. PubMed ID: 12901324
[TBL] [Abstract][Full Text] [Related]
38. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
39. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
40. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission.
Baron F; Storb R
Curr Opin Hematol; 2007 Mar; 14(2):145-51. PubMed ID: 17255792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]